ReviewClinical, cosmetic and investigational dermatology2026
Bibliometric Analysis of Traditional Chinese Medicine in Treating Eczema.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eczema, particularly atopic dermatitis (AD), is a chronic relapsing inflammatory skin disease. While biologics and JAK inhibitors have advanced treatment, challenges remain in sustained remission and long-term safety. Traditional Chinese Medicine (TCM) may offer complementary or steroid-sparing benefits via anti-inflammatory, immunomodulatory, and barrier-repair mechanisms. This bibliometric analysis retrieved English publications from Web of Science (WOS), PubMed, and Scopus (2010-2025). After deduplication using NoteExpress and manual screening, 158 publications were included, CiteSpace with VOSviewer were used for visualization. Publications rose markedly after 2019, with China leading output. Research foci shifted from clinical efficacy to mechanisms and network pharmacology. Limitations include weak international collaboration and limited study of non-AD eczema. Future priorities include multi-center trials, mechanistic research on TCM formulas, validated outcomes (EASI, DLQI, TEWL), and expanded subtype coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.